2026年6月最新影响因子数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
体验更多LetPub AI科研工具 >> | |
| 近期推荐： | 热 全流程投稿协助套餐服务 | 热 SCI论文AI润色+人工QC服务 | 新 聚合物期刊JPM征稿｜IF持续上升 + APC折扣 | 热 Springer Nature特刊征稿 |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Liver Cancer LIVER CANCER （此期刊被最新的JCR期刊SCIE收录） LetPub评分 8.5
51人评分
我要评分
声誉 9.9 影响力 7.7 速度 7.0 | |||||||||||||||||||||||||||||||
| 期刊ISSN | 2235-1795 | 安装APP，查看期刊最新消息
| ||||||||||||||||||||||||||||||
| E-ISSN | 1664-5553 | |||||||||||||||||||||||||||||||
| 2025-2026最新影响因子 （数据来源于搜索引擎） | 10.5 点击查看影响因子趋势图 | |||||||||||||||||||||||||||||||
| 实时影响因子 | 截止2026年5月06日：10.37 | |||||||||||||||||||||||||||||||
| 2025-2026自引率 | 10.5%点击查看自引率趋势图 | |||||||||||||||||||||||||||||||
| 五年影响因子 | 11.5 | |||||||||||||||||||||||||||||||
| JCI期刊引文指标 | 1.82 | |||||||||||||||||||||||||||||||
| h-index | 25 | |||||||||||||||||||||||||||||||
| CiteScore （ 2026年6月最新版） |
| |||||||||||||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||||||||||||
| 期刊官方网站 | https://www.karger.com/Journal/Home/255487 | |||||||||||||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||||||||||||
| 期刊投稿网址 | https://www.manuscriptmanager.net/sLib/v4/login.php?paramScreen=bcN+I3CS9qwx940f/BPvJ/MzoRzVWdbdT6ew8aLp8Yk= | |||||||||||||||||||||||||||||||
| 该期刊中国学者近期发文 - New | Impact of Procedural Quality on Outcomes of Transarterial Chemoembolization for Hepatocellular Carcinoma: A Multicenter Study Author: Jiang, Nan; Zhang, Wen; Peng, Zhenwei; Liu, Chang; Xiao, Yu-Dong; Yang, Wei-Zhu; Ding, Rong; Yin, Li-Nan; Jiang, Jian-Qiang; Ni, Cai-Fang; Yan, Zhi-Ping; Kuang, Ming; Teng, Gao-Jun; Zhong, Bin-Yan Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000550734 Impact of Age on Patient-Reported Outcomes with First-Line Camrelizumab plus Rivoceranib versus Sorafenib in Adults with Unresectable Hepatocellular Carcinoma: Post Hoc Analyses of the CARES-310 Open-Label, Randomized, Phase 3 Trial Author: Chan, Stephen Lam; Kaseb, Ahmed Omar; Alexander, Laura; Meng, Xianzhang; Ryan, Kristin; Shi, Wei; Vogel, Arndt Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000551156 Age-Adjusted Charlson Comorbidity Index Guides Risk Stratification for Hepatocellular Carcinoma Patients Treated with TACE Combined with Immune Checkpoint Inhibitors and Targeted Therapy: A Multicenter Retrospective Cohort Study Author: Lin, Xiaohan; Zhang, Shiying; Ong, Meiching; Fang, Jun; Mu, Aibo; Wang, Kui; Xu, Li; Bi, Xinyu; Liu, Xiufeng; Chen, Yongjun; Sun, Huichuan; Ling, Qi Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000550356 Gd-EOB-DTPA-Enhanced Magnetic Resonance Imaging for Predicting Immunotherapy Response in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis Author: Xie, Wenbo; Sun, Linmao; Fu, Yumin; Liang, Shuhang; Liu, Yao; Wang, Jiabei; Liu, Lianxin Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000550938 | |||||||||||||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Liver Cancer的语言要求，还能让Liver Cancer编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Liver Cancer编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||||||||||||
| 通讯方式 | ALLSCHWILERSTRASSE 10, BASEL, SWITZERLAND, CH-4009 | |||||||||||||||||||||||||||||||
| 出版商 | S. Karger AG | |||||||||||||||||||||||||||||||
| 涉及的研究方向 | Medicine-Oncology | |||||||||||||||||||||||||||||||
| 出版国家或地区 | SWITZERLAND | |||||||||||||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||||||||||||
| 出版周期 | ||||||||||||||||||||||||||||||||
| 出版年份 | 0 | |||||||||||||||||||||||||||||||
| 年文章数 | 66点击查看年文章数趋势图 | |||||||||||||||||||||||||||||||
| Gold OA文章占比 | 100.00% | |||||||||||||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 86.36% | |||||||||||||||||||||||||||||||
| WOS期刊JCR分区 （ 2025-2026年最新版） | WOS分区等级：1区
| |||||||||||||||||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版：不在预警名单中 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||||||||||||
  | ||||||||||||||||||||||||||||||||
| 《新锐期刊分区表》 （ 2026年3月发布） | 点击查看期刊分区表趋势图
| |||||||||||||||||||||||||||||||
| 期刊分区表 （ 2025年3月升级版） |
| |||||||||||||||||||||||||||||||
| 期刊分区表 （ 2023年12月旧的升级版） |
| |||||||||||||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) | |||||||||||||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2235-1795%5BISSN%5D | |||||||||||||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 16 Weeks | |||||||||||||||||||||||||||||||
| 平均录用比例 | 网友分享经验： | |||||||||||||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Liver Cancer顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Impact of Procedural Quality on Outcomes of Transarterial Chemoembolization for Hepatocellular Carcinoma: A Multicenter Study Author: Jiang, Nan; Zhang, Wen; Peng, Zhenwei; Liu, Chang; Xiao, Yu-Dong; Yang, Wei-Zhu; Ding, Rong; Yin, Li-Nan; Jiang, Jian-Qiang; Ni, Cai-Fang; Yan, Zhi-Ping; Kuang, Ming; Teng, Gao-Jun; Zhong, Bin-Yan Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000550734 PubMed DOI |
| 2. | Impact of Age on Patient-Reported Outcomes with First-Line Camrelizumab plus Rivoceranib versus Sorafenib in Adults with Unresectable Hepatocellular Carcinoma: Post Hoc Analyses of the CARES-310 Open-Label, Randomized, Phase 3 Trial Author: Chan, Stephen Lam; Kaseb, Ahmed Omar; Alexander, Laura; Meng, Xianzhang; Ryan, Kristin; Shi, Wei; Vogel, Arndt Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000551156 PubMed DOI |
| 3. | Age-Adjusted Charlson Comorbidity Index Guides Risk Stratification for Hepatocellular Carcinoma Patients Treated with TACE Combined with Immune Checkpoint Inhibitors and Targeted Therapy: A Multicenter Retrospective Cohort Study Author: Lin, Xiaohan; Zhang, Shiying; Ong, Meiching; Fang, Jun; Mu, Aibo; Wang, Kui; Xu, Li; Bi, Xinyu; Liu, Xiufeng; Chen, Yongjun; Sun, Huichuan; Ling, Qi Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000550356 PubMed DOI |
| 4. | Gd-EOB-DTPA-Enhanced Magnetic Resonance Imaging for Predicting Immunotherapy Response in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis Author: Xie, Wenbo; Sun, Linmao; Fu, Yumin; Liang, Shuhang; Liu, Yao; Wang, Jiabei; Liu, Lianxin Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000550938 PubMed DOI |
| 5. | Survival Outcomes, Recurrence Patterns, and Its Corresponding Therapeutic Management after Conversion Therapy Followed by Curative Resection for Hepatocellular Carcinoma: A Real-World Study Author: Xiao, Rui; Yang, Zhenyun; Zheng, Zehao; Liu, Na; Yu, Wei; Lin, Qingyang; Chen, Jinbin; Wang, Juncheng; Zhou, Zhongguo; Zhang, Yaojun; Chen, Minshan; Hu, Dandan Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000550954 PubMed DOI |
| 6. | Stable Disease without Tumor Shrink Cannot Benefit from Surgery following Immune-Based Therapy in Potentially Resectable Hepatocellular Carcinoma Author: He, Tian; Xu, Bin; Yang, Zi-Yue; Zhou, Shi-Qi; Wang, Zi-Yi; Wang, Lu-Na; Zhong, Cheng-Jie; Shi, Huan-Chen; Li, Hui; Hu, Bo; Zhu, Xiao-Dong; Shen, Ying-Hao; Gao, Qiang; Zhou, Jian; Fan, Jia; Sun, Hui-Chuan; Huang, Cheng Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000550497 PubMed DOI |
| 7. | Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study Author: Pan, Zhaolong; Liu, Dongming; Cao, Junbo; Fu, Linlin; Zhang, Xihao; Zhu, Xiaodong; Pan, Yangxun; Liu, Jianwei; Han, Chuangye; Jin, Renan; Shen, Shunli; Zhang, Xiaoyun; Liu, Hongzhi; Yang, Xiaobo; Hu, Kuan; Shi, Xiaoyi; Wang, Dongxu; Zhao, Yang; Zhong, Jianhong; Xiang, Bangde; Gu, Shanzhi; Li, Tao; Zhang, Shuijun; Zhou, Ledu; Zhao, Haitao; Zeng, Yongyi; Wen, Tianfu; Kuang, Ming; Liang, Xiao; Peng, Tao; Wang, Kui; Xu, Li; Li, Huikai; Song, Tianqiang; Sun, Huichuan; Zhang, Wei Journal: LIVER CANCER. 2025; Vol. , Issue , pp. -. DOI: 10.1159/000545545 PubMed DOI |
| 8. | Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter Study Author: Yang, Da-Long; Peng, Ning; Nong, Jun-Liang; Chen, Kang; Su, Ze; Yu, Ya-Qun; Ye, Lin; Zeng, Fan-Jian; Liu, Shao-Ping; Yan, Yi-He; Wang, Xue-Yao; Yao, Hong-Bing; Yang, Fu-Quan; Li, Wen-Feng; Qin, Chuang; Wu, Ming-Song; Yang, Yong-Yu; Dong, Xiao-Feng; Li, Mian-Jing; Liu, Jie; Liang, Yong-Rong; Wu, Pei-Sheng; Zhong, Teng-Meng; Lai, Yong-Cheng; Chen, Yao-Zhi; Pang, Qing-Qing; Wang, Guo-Dong; Li, Fu-Xin; Mao, Xian-Shuang; Chen, Shu-Chang; Ou, Jun-Jie; Huo, Rong-Rui; Liang, Xiu-Mei; Xiang, Bang-De; Ma, Liang; Zhong, Jian-Hong Journal: LIVER CANCER. 2025; Vol. , Issue , pp. -. DOI: 10.1159/000546052 PubMed DOI |
| 9. | Matching-Adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma Author: Zhang, Yi-Min; Wu, Xin-Tong; Yi, Jun-Zhe; Xu, Jie; Zhang, Yu-Nan; Lyu, Ning; Zhao, Ming Journal: LIVER CANCER. 2025; Vol. , Issue , pp. -. DOI: 10.1159/000545891 PubMed DOI |
| 10. | Asian Conference on Tumor Ablation Guidelines for Hepatocellular Carcinoma Author: Shiina, Shuichiro; Tateishi, Ryosuke; Choi, Joon Il; Kim, So Yeon; Meng, Zhiqiang; Shen, Lujun; Lu, Sheng-Nan; Hwang, Jen-I.; Tobari, Maki; Maruyama, Hitoshi; Batsaikhan, Terguunbileg; Deng, Qing; Canseco, Lariza Marie; Asaoka, Yoshinari; Lin, Shi-Ming; Huang, Kai-Wen; Rhim, Hyunchul; Liang, Ping; Pua, Uei; Tanaka, Masatoshi; Wu, Peihong Journal: LIVER CANCER. 2025; Vol. , Issue , pp. -. DOI: 10.1159/000544976 PubMed DOI |
|
|
  | ||||||||||||||||
|
投稿状态统计： 我要评分： | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范？试试稿件自查工具，一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验：共0条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
投稿信 (Cover Letter) 模板
